EWS
TEVA icon

Eagle Wealth Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Eagle Wealth Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,918
Closed -$383K – 109
2025
Q1 		$383K Hold
24,918
– – 0.24% 52
2024
Q4 		$549K Hold
24,918
– – 0.4% 38
2024
Q3 		$449K Buy
+24,918
New +$436K 0.33% 48

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Eagle Wealth Strategies's TEVA Position: Q2 2025 in Review

Eagle Wealth Strategies sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 24,918 shares — an estimated $383K sold.

Eagle Wealth Strategies first reported a position in TEVA in Q3 2024 and held it in 3 quarters. The position peaked at $549K in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Eagle Wealth Strategies reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Eagle Wealth Strategies sold 24,918 Teva Pharmaceuticals shares in Q2 2025, an estimated $383K.
  • Eagle Wealth Strategies first reported a position in Teva Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Eagle Wealth Strategies's Teva Pharmaceuticals position peaked at $549K in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Eagle Wealth Strategies's 13F filing for Q2 2025, filed 17 Jul 2025.